WASHINGTON (dpa-AFX) - AbbVie Inc. (ABBV) announced Wednesday that Health
Canada approved Qulipta, also known as atogepant, for preventing migraines in
adults with at least four migraine days per month.

The approval was based on a Phase 3 PROGRESS trial that showed a significant
reduction in monthly migraine days with Qulipta 60 mg once daily for adult
patients with chronic migraine.

The company stated that Qulipta is the first oral, small-molecule CGRP receptor
antagonist approved for both episodic and chronic migraine prevention and is
available in three strengths - 10 mg, 30 mg, and 60 mg.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX